08.24.26 -- The U.S. Supply-Chain Uncovered: A Superior Search For Domestic Suppliers

Technology can transform the entire biopharma production process chain. Using integrated process models, machine learning, and genetic algorithms has made production faster and more efficient.

Discover how effective technology transfer strategies can streamline scale-up, maintain product quality, and enable successful clinical and commercial manufacturing.

As demand for GLP-1s and biologics accelerates and timelines compress, it's become more crucial that pharmaceutical companies stay competitive and bring therapies to market by partnering with a CDMO.

Through early collaboration and advanced aseptic technology, organizations can overcome complex formulation challenges to ensure safe, effective treatments reach patients more efficiently than before.

View antibody-oligonucleotide conjugate design, highlighting antibody formats, linker strategies, and screening methods to optimize delivery, stability, and gene-targeting therapeutic performance.

How robotic, gloveless fill‑finish cuts aseptic risk, enables flexible containers, and scales manufacturing — connecting advanced automation to patient safety and operational efficiency.

Assimilate how a people-first talent strategy, purpose-driven culture, and cross-functional collaboration come together to support scalable growth and operational excellence in commercial manufacturing.

We partnered with a global pharma company to optimize biologic production, increasing output by 50% and reducing batch release times by up to 30%.

Platforms incorporating high throughput in silico screening, in vitro expression, and immunosafety of multi-specific molecules can help mitigate potential developability risks and accelerate timelines.

Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill/finish is successful. Review the challenges of transitioning a promising drug candidate.

Successful E&L planning starts before testing begins. Aligning study design, partner expertise, and timing helps teams focus on the right risks, avoid surprises, and support stronger development.